ETF Research Center

The Global X Genomics & Biotechnology ETF seeks to track the performance, before fees and expense, of the Solactive Genomics Index.

FUND BASICS
Category	US Equities
Fund Sponsor	Global X
Website	www.globalxfunds.com
Inception date	Apr 08, 2019
Assets (mns)	$21
Currency	USD
Expense ratio	68 bp
Distributions	Quarterly

FUND STRUCTURE
Regulation	Open-Ended Fund
Custodian
Weighting
Index replication
Uses derivatives	No
Options available	No

SECTOR BREAKDOWN

CONSTITUENT BREAKDOWN
No. of constituents	36
Wgt avg mkt cap (mns)	$10,106
Large cap (>$10bn)	24.0%
Mid cap ($2-10bn)	34.5%
Small cap (<$2bn)	41.6%
Developed mkts	100.0%
Emerging mkts	0.0%

TOP TEN HOLDINGS
Total	48.5 %
SAREPTA THERAPEUTICS INC	5.6 %
ULTRAGENYX PHARMACEUTICAL IN	5.3 %
ARROWHEAD PHARMACEUTICALS, INC.	5.2 %
PTC THERAPEUTICS INC	5.2 %
ALNYLAM PHARMACEUTICALS INC	4.8 %
BIOMARIN PHARMACEUTICAL INC	4.7 %
QIAGEN NV	4.6 %
VERTEX PHARMACEUTICALS INC	4.5 %
AGILENT TECHNOLOGIES INC	4.4 %
BLUEBIRD BIO INC	4.2 %

TOP COUNTRY EXPOSURE
	UNITED STATES	83.2 %
	NETHERLANDS	9.2 %
	CHINA	3.9 %
	SWITZERLAND	3.0 %
	SINGAPORE	0.4 %

HISTORICAL PERFORMANCE info

	Custom date range	Compare to
	thru

Standardized Annual Returns (thru December 31)
Year-to-date	1 year	5 years	10 years	Since Incep.
8.9%	--	--	--	8.9%

Market Correlations
versus...	Beta	R-squared
S&P500	--	--
MSCI EAFE	--	--
MSCI Emg. Mkts.	--	--

Technical Indicators
Recent close	$15.83
30d moving avg.	$15.95
Annualized volatility	0.0%
Short interest (ETF)	0.4%
Relative strength (RSI)	53

Liquidity measures
Avg. volume (thou.)	10
Turnover	0.8%
Bid/Ask (% of price)	0.24%
ADV underlying (mns)	$2,537

Distributions

FINDING ALTERNATIVE FUNDS

Below is a list of 20 potential alternatives to the Global X Genomics & Biotechnology ETF based on the alternatives' overlap in portfolio holdings with GNOM. Consider funds with lower expense ratios and/or higher ALTAR Score™ ratings as possible alternatives.

Benchmark ticker:

GNOM

Expense:

68 bp

ALTAR Score™:

-5.5%

ALTERNATIVE ETFs BASED ON OVERLAP WITH GNOM
Ticker	Fund Name	Overlap¹ vs GNOM (%)	Expense ratio (bp)	Savings vs GNOM (bp)	ALTAR Score™ (%)	ALTAR vs GNOM (%)
FBT	First Trust NYSE-ARCA Biotechnology	30.1	57	11	-0.7	+4.8
BBH	VanEck Vectors Biotech	25.7	35	33	4.4	+9.9
XBI	SPDR S&P Biotech ETF	24.4	35	33	-5.0	+0.5
IDNA	iShares Genomics Immunology and Healthcare	23.2	47	21	-3.2	+2.4
BTEC	Principal Healthcare Innovators Index	20.0	42	26	-4.1	+1.5
IBB	iShares NASDAQ Biotechnology	19.7	47	21	1.0	+6.5
ARKG	ARK Genomic Revolution Multi-Sector	19.2	75	-7	-2.9	+2.7
ARKK	ARK Innovation	17.9	75	-7	-4.1	+1.5
BBP	BioShares Biotech Products	15.3	79	-11	-3.7	+1.8
HTEC	Robo Global Healthcare Technology and Innovation	14.3	68	0	-0.6	+5.0
BBC	Virtus LifeSci Biotech Clinical Trials	12.9	79	-11	-5.2	+0.3
SBIO	ALPS Medical Breakthroughs	12.4	50	18	-5.0	+0.5
IEIH	iShares Evolved U.S. Innovative Healthcare	11.9	18	50	3.8	+9.3
GDNA	Goldman Sachs Motif Human Evolution	11.3	50	18	1.0	+6.5
CNCR	Loncar Cancer Immunotherapy	10.4	79	-11	-4.0	+1.6
PTH	Invesco DWA Healthcare Momentum	7.5	60	8	-3.5	+2.0
QQXT	First Trust NASDAQ-100 Ex-Tech	6.6	60	8	4.8	+10.4
RYH	Invesco S&P Equal Weight Healthcare	6.4	40	28	6.7	+12.2
FHLC	Fidelity MSCI Health Care	6.4	8	60	5.5	+11.0
VHT	Vanguard Health Care	6.3	10	58	5.5	+11.1

¹Overlap is the percentage of holdings by weight that are identical. For example, if Fund A has a 2% position in Apple, Inc. (AAPL) and Fund B has a 5% position, their overlapping position in AAPL is 2%.

Content on this tab for subscribers only**

RESULTS & ESTIMATES

	2014	2015	2016	2017	2018	2019E	2020E
Sales per share	**	**	**	**	**	**	**
Earnings per share	**	**	**	**	**	**	**
Dividends per share	**	**	**	**	**	**	**
Book value per share	**	**	**	**	**	**	**

Sales per share growth		**%	**%	**%	**%	**%	**%
EPS growth		**%	**%	**%	**%	**%	**%

Sales per share growth		**%	**%	**%	**%	**%	**%
EPS growth		**%	**%	**%	**%	**%	**%

OTHER FUNDAMENTAL METRICS

Long term EPS growth est.	**%		Debt-to-equity	**x
Asset turnover	**%		Assets-to-equity	**x

Return on equity

Revision activity*

*Six months ago = 100

Net margins

Compound annual growth rates

Content on this tab for subscribers only

VALUATION METRICS

	2018	2019E	2020E
Price-to-sales	**	**	**
Price-to-earnings	**	**	**
Price-to-cash flow	**	**	**
Price-to-growth	**	**	**
Price-to-book value	**	**	**
Yield	**	**	**

Historical valuation trends

Forward multiple:	Global X Genomics & Biotechnology
Relative to:	S&P500	MSCI EAFE	MSCI Emg. Mkts.	Other ETF:

AVOID

Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant.

ALTAR Score™

Calculation of ALTAR Score™
Avg. Return on Equity	-39.8	%
Divided by: Fwd. P/BV	8.2	x
Less: Expense ratio	68	bp
Equals: ALTAR Score	-5.5	%

More information on ALTAR Score™

MODERN PORTFOLIO THEORY info

CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS

COMPOSITE RATING	1.35	CATEGORY AVERAGE	1.55

The composite rating is a weighted average of analysts' consensus recommendations for individual ETF constituents, based on the following scale: BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3. Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation.